Kevin Williams to High-Throughput Screening Assays
This is a "connection" page, showing publications Kevin Williams has written about High-Throughput Screening Assays.
Connection Strength
1.267
-
Brantley SJ, Cotten SW, Lamson DR, Smith GR, Liu R, Williams KP. Discovery of small molecule inhibitors for the C.?elegans caspase CED-3 by high-throughput screening. Biochem Biophys Res Commun. 2017 09 23; 491(3):773-779.
Score: 0.594
-
Williams KP, Allensworth JL, Ingram SM, Smith GR, Aldrich AJ, Sexton JZ, Devi GR. Quantitative high-throughput efficacy profiling of approved oncology drugs in inflammatory breast cancer models of acquired drug resistance and re-sensitization. Cancer Lett. 2013 Aug 28; 337(1):77-89.
Score: 0.445
-
Tarpley M, Oladapo HO, Strepay D, Caligan TB, Chdid L, Shehata H, Roques JR, Thomas R, Laudeman CP, Onyenwoke RU, Darr DB, Williams KP. Identification of harmine and ?-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies. Eur J Pharm Sci. 2021 Jul 01; 162:105821.
Score: 0.192
-
Arora J, Sauer SJ, Tarpley M, Vermeulen P, Rypens C, Van Laere S, Williams KP, Devi GR, Dewhirst MW. Inflammatory breast cancer tumor emboli express high levels of anti-apoptotic proteins: use of a quantitative high content and high-throughput 3D IBC spheroid assay to identify targeting strategies. Oncotarget. 2017 Apr 18; 8(16):25848-25863.
Score: 0.036